This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (19)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Connective Tissue Diseases  • Dermatologic Disorders, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Tamara Salam Housman, MD; Joseph L. Jorizzo, MD; Martha A. McCarty, MS, PA-C; Sarah E. Grummer; Alan B. Fleischer, Jr, MD; Paul G. Sutej, MD

Arch Dermatol. 2003;139:50-54.

Background  Thalidomide is an anti-inflammatory agent and an immunomodulator that inhibits the production of tumor necrosis factor . It has shown promise as a treatment option for the cutaneous manifestations of lupus erythematosus (LE).

Objective  To assess the degree of clinical response per subtype of cutaneous lupus, the duration of therapy before documented clinical improvement, and the incidence of adverse effects, including peripheral neuropathy, with low-dose thalidomide therapy at 100 mg daily in the treatment of refractory cutaneous lesions of LE.

Methods  This retrospective medical record review of patients with refractory cutaneous manifestations of LE is one of the largest modern series in the literature. There were 29 patients seen at the Department of Dermatology, Wake Forest University School of Medicine (Winston-Salem, NC), who were unresponsive to conventional agents including antimalarial agents, and who started treatment between 1998 and 2000. Twenty-three patients who took the drug for 1 month or more were included in the analysis. Clinical responses were assessed by the investigators based on statements of improvement listed in the clinic notes and were categorized as "no response," "partial response," and "complete response." Partial response was classified as either 75% or greater or less than 75% improvement. The incidence of adverse effects including peripheral neuropathy was determined.

Results  Of the 23 patients, 17 (74%) demonstrated complete resolution of the cutaneous manifestations of LE, whereas 3 patients (13%) demonstrated 75% or greater partial improvement; 3 patients (13%) had less than 75% partial clinical improvement; and 21 patients (91%) who demonstrated a complete or partial response did so within 8 weeks of initiating thalidomide therapy.

Conclusions  Based on the results of this case series, we believe that thalidomide should be given prime consideration as a treatment for antimalarial drug–resistant interface lesions of LE. The design of prospective, randomized, double-blind, placebo-controlled trials for this indication is warranted.

From the Departments of Dermatology (Drs Housman, Jorizzo, and Fleischer and Mss McCarty and Grummer) and Internal Medicine–Section on Rheumatology (Dr Sutej), Wake Forest University School of Medicine, Winston-Salem, NC. The authors have no proprietary interests in thalidomide or any competing product.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients
Wozniacka et al.
Lupus 2006;15:268-275.
ABSTRACT  

Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients
Coelho et al.
Lupus 2005;14:434-439.
ABSTRACT  

Thalidomide Treatment for Prurigo Nodularis in Human Immunodeficiency Virus-Infected Subjects: Efficacy and Risk of Neuropathy
Maurer et al.
Arch Dermatol 2004;140:845-849.
ABSTRACT | FULL TEXT  

Thalidomide neurotoxicity: Prospective study in patients with lupus erythematosus
Briani et al.
Neurology 2004;62:2288-2290.
ABSTRACT | FULL TEXT  

Low-Dose Thalidomide Is Useful for Cutaneous Lupus Erythematosus
Journal Watch Dermatology 2003;2003:6-6.
FULL TEXT